
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics is expected to continue its positive momentum in the coming years as it progresses towards the approval and launch of its flagship product candidate, nomlabofusp, for the treatment of Friedreich's ataxia. In addition, the company's novel cell penetrating peptide technology platform has the potential to address other rare diseases, providing a promising pipeline for future growth. While the current cash runway may pose some constraints, the company may benefit from potential monetization opportunities of a Priority Review Voucher upon approval. This, along with a potential secondary offering, could help address the need for additional funding to support the regulatory process. Overall, the potential of nomlabofusp to become a disease-modifying treatment for FA patients, coupled with the company's strong technological foundation, makes Larimar Therapeutics an attractive investment opportunity for long-term growth.
Bears say
Larimar Therapeutics is a clinical-stage biotechnology company with a high-risk, single product development strategy for their lead program, nomlabofusp, which targets a niche market for Friedreich's ataxia. Despite some promising clinical data, there are significant risks related to remaining regulatory approvals, manufacturing, and possible equity dilution which impact the company's valuation of $1.19B and $1.33B in total enterprise and firm value, respectively. Additionally, the company's reliance on external funding to advance their pipeline may lead to delays or termination of development campaigns.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares